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Intracerebral hemorrhage (ICH) is the stroke subtypewith the worst prognosis and has no established acute treatment. ICH is classified as
lobar or nonlobar based on the location of ruptured blood vessels within the brain. These different locations also signal different under-
lying vascular pathologies. Heritability estimates indicate a substantial genetic contribution to risk of ICH in both locations. We report a
genome-wide association study of this condition that meta-analyzed data from six studies that enrolled individuals of European
ancestry. Case subjects were ascertained by neurologists blinded to genotype data and classified as lobar or nonlobar based on brain
computed tomography. ICH-free control subjects were sampled from ambulatory clinics or random digit dialing. Replication of signals
identified in the discovery cohort with p < 1 3 106 was pursued in an independent multiethnic sample utilizing both direct and
genome-wide genotyping. The discovery phase included a case cohort of 1,545 individuals (664 lobar and 881 nonlobar cases) and a
control cohort of 1,481 individuals and identified two susceptibility loci: for lobar ICH, chromosomal region 12q21.1 (rs11179580,
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The replication included a case cohort of 1,681 individuals (484 lobar and 1,194 nonlobar cases) and a control cohort of 2,261 individ-
uals and corroborated the association for 1q22 (p ¼ 6.5 3 104; meta-analysis p ¼ 2.2 3 1010) but not for 12q21.1 (p ¼ 0.55; meta-
analysis p ¼ 2.6 3 105). These results demonstrate biological heterogeneity across ICH subtypes and highlight the importance of
ascertaining ICH cases accordingly.Introduction
Stroke is the most devastating manifestation of cerebrovas-
cular disease and the second leading cause of death and
acquired disability worldwide.1,2 Strokes are classified as
ischemic or hemorrhagic (85% and 15% in people of Euro-
pean descent, respectively), and spontaneous intracerebral
hemorrhage (ICH [MIM 614519]) is by far the most com-
mon type of hemorrhagic stroke.3 Largely a disease of the
elderly, ICH occurs when cerebral vessels rupture and
is associated with 40%–50% 3-month mortality as well
as sustained disability in more than half of survivors.4,5
The incidence of ICH is expected to rise in coming years
because of increases in life expectancy and widespread
use of antithrombotic therapy in the elderly.6,7 Although
treatment of hypertension partially reduces the risk of
initial or recurrent ICH,8 there are no established acute
treatments for this condition. Therefore, identification of
biological pathways that could eventually be targeted by
novel therapeutic strategies is vital to reducing the health
care burden associated with this disease.
Histopathological observations demonstrate that the
underlying cerebral small vessel disease differs according
to the location of the ICHwithin the brain. Lobar ICH orig-
inates in the cerebral cortex or cortical-subcortical junction
and is most commonly associated with cerebral amyloid
angiopathy.9 Nonlobar ICH originates in deep structures
of cerebral hemispheres, brainstem, and cerebellum and
tends to be associated with what is typically called hyper-
tensive vasculopathy.10 This heterogeneity in underlying
biological processes leading to different ICH subtypes
has been corroborated by epidemiologic,11 neuroimag-
ing,12 and genetic studies.13,14 A large multicenter candi-
date gene study undertaken by the International Stroke
Genetics Consortium in the same populations utilized in
the present study established that the epsilon variants of
APOE (MIM 107741), known to be risk factors for sporadic
cerebral amyloid angiopathy, are associated at genome-
wide significance levels specifically with lobar ICH.13 Like-
wise, it was subsequently found that the burden of risk
alleles for high blood pressure associates specifically with
nonlobar ICH.14
Heritability estimates indicate that common genetic
variation plays a substantial role in risk of both ICH sub-
types beyond APOE and blood-pressure-related variants.15
Identification of these genetic contributors would have a
significant impact on the field of stroke, because it could
help uncover specific biological pathways hitherto unsus-
pected to play a role in this condition that could be
targeted by novel therapeutic strategies. In this study
we meta-analyzed data from six previously unpublished
genome-wide association studies of ICH that enrolled sub-512 The American Journal of Human Genetics 94, 511–521, April 3, 2jects of European ancestry in the United States and Europe
under the auspices of the International Stroke Genetics
Consortium, with subsequent replication of identified sus-
ceptibility loci in an independent study of ICH.Subjects and Methods
Participating Studies
Case and control subjects included in the discovery phase were
subjects of European ancestry aged >55 years in the Genetics
of Cerebral Hemorrhage with Anticoagulation13 (GOCHA) study
(multicenter study in the US) and aged >18 years in the Genetic
and Environmental Risk Factors for Hemorrhagic Stroke16
(GERFHS) studies I and II in Cincinnati, OH; Hospital del Mar
Intracerebral Hemorrhage17 study and Vall d’Hebron Hospital
ICH18 study in Barcelona, Spain; Jagiellonian University Hemor-
rhagic Stroke Study19 in Krakow, Poland; and the Lund Stroke
Register20 study in Lund, Sweden. Because of their limited sample
sizes, data from the four European studies (ESs) were analyzed
together for the purposes of quality control, imputation, and
association testing.
Subjects
Cases were ascertained across participating studies according to
predefined standardized criteria. Spontaneous ICH was defined
as a new and acute neurological deficit with compatible brain im-
aging (computed tomography or magnetic resonance imaging)
showing the presence of intraparenchymal bleeding. According
to standard research and clinical practice in the field,3 ICH loca-
tion was assigned based on admission images by neurologists
who were blinded to genotype data. ICH originating at the cere-
bral cortex or cortical-subcortical junction (with or without
involvement of subcortical white matter) was defined as lobar,
and ICH originating at the thalamus, internal capsule, basal
ganglia, deep periventricular white matter, cerebellum, or brain
stem was defined as nonlobar. Exclusion criteria included trauma,
brain tumor, hemorrhagic transformation of ischemic stroke,
vascular malformation, and any other cause of secondary ICH.
Control subjects were ICH-free individuals enrolled from the
same population that gave rise to the case subjects at each partici-
pating study site, aged >55 years (GOCHA) and >18 years
(GERFHS and ESs). Control subjects were sampled by random digit
dialing in GERFHS and from ambulatory clinics in the remainder
of the studies.
All studies were approved by the Institutional Review Board or
ethics committee at each participating site. Participants provided
informed consent; when subjects were not able to communicate,
consent was obtained from their legal proxies.
Genome-wide Genotyping and Quality Control
Case and control subjects were genotyped with Affymetrix 6.0
in GERFHS and with Illumina HumanHap610-Quad in GOCHA
and ESs. Case and control subjects from each study were geno-
typed side-by-side on the same plates with the exception of the
replication controls from the Cincinnati Control Cohort (CCC)014
and Genomic Control Cohort (GCC), which were genotyped from
separate studies. Plate-to-plate variability was assessed by compar-
ison of SNP call and error rates. Standardized prespecified quality-
control procedures21 were implemented separately in GOCHA,
GERFHS, and ESs. These filters excluded SNPs with genotype call
rate <0.95, significant differential missingness between case and
control subjects (p < 0.05), deviation from Hardy-Weinberg equi-
librium (p < 1 3 106), or minor allele frequency (MAF) <0.01. At
the subject level, quality control excluded individuals with geno-
type call rate of <95%; inconsistency between self-reported and
genotypic gender; an inferred first- or second-degree relative in
the sample identified on the basis of pairwise allele sharing esti-
mates (estimated genome proportion shared identical by descent;
p > 0.1875); and extreme genome-wide heterozygosity f statistic,
defined as >5 times its standard deviation.Population Stratification
After quality-control procedures, principal-components anal-
ysis22 was implemented separately in GOCHA, GERFHS, and
ESs, incorporating genotype data from 1000 Genomes23 popula-
tions. Population outliers were identified and removed by visual
inspection of principal component plots, and the first four prin-
cipal components were subsequently included in regression
models fitted for association testing. Principal-component and
identity-by-descent analyses were performed via a pruned subset
of independent SNPs (61,325 SNPs in GOCHA, 95,013 in
GERFHS, and 64,728 in ESs) to account for potential biases intro-
duced by LD structure.Imputation
After quality-control procedures and principal component anal-
ysis, imputation was performed separately in GOCHA, GERFHS,
and ESs via IMPUTE2 v.2.224 and 1000Genomes23 integrated refer-
ence panels (Phase I interim release inNCBI build 37). The number
of SNPs that entered the imputation process were 525,752,
795,240, and 532,149 for GOCHA, GERFHS, and ESs, respectively.
Postimputation filters excluded imputed SNPs with MAF <0.01,
IMPUTE2 information score <0.7, confidence score <0.9, and
missing estimates in association testing for 1 or more studies.Genome-wide Association Testing
Given the biological differences in ICH subtypes outlined in the
introduction and after a prespecified analysis plan, genome-wide
association analyses were computed separately for all ICH (lobar
and nonlobar combined), for lobar ICH, and for nonlobar ICH.
These analyses were completed separately in GOCHA, GERFHS,
and ESs via logistic regression, assuming additive genetic effects
(1-degree-of-freedom additive trend test) and adjusting for age,
gender, and principal components. In secondary analysis, associa-
tion testing was carried out separately in each European study.
Association p values obtained in GOCHA, GERFHS, and ESs were
meta-analyzed via the inverse normal method weighting by
sample size as implemented in METAL,25 and heterogeneity of
pooled estimates was quantified by computing Cochrane’s Q
and corresponding p and I2. After recent GWAS meta-analysis,26
only SNPs with available estimates in all three data sets are
reported. Quantile-quantile plots were utilized to assess systematic
inflation in association results resulting from population stratifica-
tion or other systematic causes of bias.
Further analyses were undertaken to evaluate the presence of
additional independent signals at each locus. Additional indepen-The Amdent signals at each locus were evaluated by conditional testing
completed by adding the dosages of the top SNP at each locus to
logistic regression models. Pairwise linkage disequilibrium (LD)
between SNPs was assessed and visualized with 1000 Genomes
Ensemble-based genome browser.27 Regional association plots
were constructed with LocusZoom software.28Replication
Replication of associations with p < 1 3 106 in the discovery
meta-analysis was pursued in case and control groups from the
Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)29
and GERFHS III16 studies, in adult control group from the
CCC,16 and GCC.16 Enrolled ICH cases and controls from
ERICH were non-Hispanic whites, African Americans, and His-
panic subjects (based on self-reported race and ethnicity) aged
>18 years from multiple study centers across the US. ICH case
subjects were ascertained with the same criteria utilized in the
discovery phase. ICH-free control subjects were sampled by
random digit dialing from the population that gave rise to the
case cohort. The CCC and GCC cohorts are population-based
cohorts of ICH-free individuals from the Greater Cincinnati
area. The CCC cohort was specifically enrolled to approximate
the age, sex, and race distribution of ICH subjects, and the
GCC was enrolled to match the population and geographic dis-
tribution of the metropolitan area. Genotyping was completed
with TaqMan assays (ERICH Study) or Affymetrix 6.0 (GERFHS
III and CCC-GCC). For the latter, preimputation quality-control
procedures, imputation, and postimputation filters were imple-
mented as described for the discovery phase. Association testing
was carried out by fitting logistic regression models and imple-
menting a 1-degree-of-freedom trend test, assuming additive
effects and including age and gender in all models. Meta-ana-
lyses across discovery and replication proceeded as described
above for the discovery phase. Replication results were consid-
ered significant at p < 0.05 and genome-wide significance was
defined as p < 5 3 108.30Overlap with Common Variants Related to Blood
Pressure
Given the well-established role of hypertension in causing ICH,
especially of nonlobar type, we specifically assessed the role in
ICH of common genetic variants known to play a role in deter-
mining blood pressure. SNPs reported to be related to blood pres-
sure at p < 1 3 105 were identified in the GWAS Catalog.31
Queried traits included blood pressure; hypertension; and
diastolic, systolic, mean, and pulse blood pressures. Association
results for these SNPs were identified for all, for lobar, and for
nonlobar ICH.Overlap with DNase I Hypersensitivity Sites
The positions of SNPs in ICH-associated loci were overlapped with
DNase I hotspot regions from the Encyclopedia of DNA Elements
(ENCODE) Project that mark generalized chromatin accessibility,
mapped for each of 125 diverse cell lines and tissues.32
The genomic region of interest for each identified loci was defined
based on the genomic variants that were in linkage disequilib-
rium with the top variant at each locus (defined as r2 > 0.5). In
addition, ICH-associated SNPs were analyzed for other overlap
with ENCODE data, including transcription factor motifs, via
RegulomeDB.33erican Journal of Human Genetics 94, 511–521, April 3, 2014 513
Table 1. Descriptive Characteristics of Participating Studies
Covariate
Discovery Replication
Multicenter, US European Studies Cincinnati, US Cincinnati, US
GOCHA HM-ICH þ VVH-ICH JUHSS LSR GERFHS I & II
ERICH/GERFHS III/
CCC-GCC
Case
Cohort
Control
Cohort
Case
Cohort
Control
Cohort
Case
Cohort
Control
Cohort
Case
Cohort
Control
Cohort
Case
Cohort
Control
Cohort
Case
Cohort
Control
Cohort
Subjects, n 298 457 212 169 122 163 116 153 797 539 1,681 2,261
Age, mean (SD) 74 (10) 72 (8) 74 (11) 71 (9) 67 (12) 65 (13) 75 (10) 75 (10) 67 (15) 66 (15) 62 (15) 43a (26)
Female, n (%) 134 (45) 231 (51) 103 (49) 77 (46) 69 (57) 93 (57) 49 (42) 69 (45) 383 (48) 243 (45) 701 (42) 1,113 (49)
Hypertension, n (%) 217 (73) 280 (61) 126 (60) 99 (64) 96 (81) 74 (45) 76 (67) 65 (43) 494 (62) 280 (52) 1,009 (60) 738b (51)
Lobar ICH, n (%) 184 (58) – 88 (40) – 51 (39) – 36 (28) – 327 (41) – 484 (29) –
Nonlobar ICH, n (%) 132 (42) – 133 (60) – 80 (61) – 94 (72) – 470 (59) – 1,197 (71) –
Abbreviations are as follows: ICH, intracerebral hemorrhage; GOCHA, Genetics of Cerebral Hemorrhage on Anticoagulation Study; HM-ICH, Hospital del Mar
Intracerebral Hemorrhage Study; VVH-ICH, Vall d’Hebron Hospital ICH Study; JUHSS, Jagiellonian University Hemorrhagic Stroke Study; LSR, Lund Stroke Register;
GERFHS, Genetic and Environmental Risk Factors for Hemorrhagic Stroke Study; ERICH, Ethnic/Racial Variations of Intracerebral Hemorrhage Study; CCC-GCC,
Cincinnati Control Cohort - Genomic Control Cohort.
aIncludes the 819 GCC pediatric control subjects with ages %18.
bExcludes the 819 GCC pediatric control subjects with no hypertension history.eQTL Analyses
Variants within each identified susceptibility locus for ICH were
evaluated for gene expression in cis via publicly available re-
sources. SNPs with p < 1 3 105 were assessed in four publicly
available eQTL databases: SCAN (SNP and CNV Annotation
Database), the NCBI and Broad Institute GTEx (Genotype-Tissue
Expression) eQTL Browsers,34 the Pritchard laboratory UChicago
eQTL browser,35 and mRNA by SNP Browser v.1.0.1.36 Gene
expression was assessed in a range of tissue and cell types,
including liver, brain, lymphoblastoid cell lines, monocytes, fibro-
blasts, and Tcells. As in previous reports,37 we defined potential cis
eQTLs as candidate SNPs associatedwith gene expressionmapping
to a 1 Mb window around each locus with p < 1 3 103.Results
After excluding subjects based on quality-control proce-
dures (n ¼ 23) and principal component analysis (n ¼
93), a case cohort of 1,545 subjects and a control cohort
of 1,481 subjects were available for association testing in
the discovery analysis (mean age 67 [SD 10], female sex
45%, Table 1). After preimputation quality-control proce-
dures, imputation to 1000 Genomes reference panels,
and postimputation quality-control filters, a total of
5,258,103 SNPs were available for association testing across
all data sets included in the discovery sample.
Susceptibility loci were identified for lobar and nonlobar
ICH, but not for all ICH (lobar and nonlobar combined)
(Figures 1A–1C, Tables S1–S3 available online). The esti-
mated inflation factors (l of 1.039, 1.016, and 1.038 for
all, lobar, and nonlobar ICH, respectively) and quantile-
quantile plots (Figure S1) indicated absence of inflation
resulting from systematic bias caused by population sub-
structure or other artifacts. Several SNPs on chromosomal
region 12q21.1, an intergenic region near TRHDE (MIM514 The American Journal of Human Genetics 94, 511–521, April 3, 2606950), were associated with lobar ICH, with peak associ-
ation detected at rs11179580 (MAF ¼ 0.24, per additional
major allele [C], odds ratio [OR] 1.56, 95% confidence
interval [CI] 1.33–1.84; p ¼ 7.0 3 108; Q ¼ 0.43, I2 ¼ 0%;
Figure 1B and Table 2). Similar results were obtained when
analyzing each European study separately (Figure S2). A
similar effect was observed for all ICH (per additional C
allele, OR 1.36, 95% CI 1.21–1.54; p ¼ 5.4 3 108; Q ¼
0.07, I2¼ 62%; Table 2 and Figure 1A), but the combination
of similar effectmagnitudes (despitedouble the sample size)
and significant increase in heterogeneity suggests that the
observed association is driven by lobar ICH. rs11179580
also showed some effect in nonlobar ICH (OR 1.25, 95%
CI 1.09–1.42, p ¼ 0.002; Table 2), indicating that the
affected biological pathway could impact both types of ce-
rebral hemorrhage. Neither adjustment for the most signif-
icant SNPs at this locus (Figure S3A) nor haplotype testing
identified additional associations of interest.
For nonlobar ICH, a susceptibility locus was identified on
chromosomal region 1q22, a region that contains PMF1
(MIM 609176) and SLC25A44 (MIM 610824). The top-asso-
ciated variant within this locus was the intronic SNP
rs2984613 (MAF 0.31; per additional major allele [C] OR
1.44, 95% CI 1.27–1.64; p ¼ 1.6 3 108; Q ¼ 0.05, I2 ¼
66%; Table 2 and Figure 1C). Although some heterogeneity
was observed for this specific variant, several SNPs within
this locus achieved genome-wide significance with substan-
tially lower heterogeneity (as showed byQ> 0.05, Table S5).
Comparable results were obtained when analyzing each Eu-
ropeanstudyseparately (FigureS2). rs2984613alsohadsome
effect in all ICH (OR1.21, 95%CI1.12–1.38, p¼ 6.03104),
probably driven by nonlobar cases, and had no effect on
lobar ICH.Neither analysis adjusting for themost significant
SNPs (Figure S3B) nor haplotype testing within these loci
identified additional associations of interest.014
Figure 1. Genome-wide Association Study Results
Genome-wide association study results of autosomal SNPs: (A) all (lobar ICH and nonlobar ICH combined), (B) lobar ICH, and (C)
nonlobar ICH. The plots show –log10-transformed p values for genotyped and imputed SNPs with respect to their physical positions.
The threshold for association at genome-wide significance (p ¼ 5 3 108) is shown by the upper dashed line, and the lower dashed
line corresponds to p ¼ 1 3 105. Landmark genes are indicated for loci that reached the threshold to pursue replication.Replication of identified associations was pursued in
1,681 case subjects (513 non-Hispanic whites, 634 African
Americans, and 534 Hispanics) and 2,261 control subjects
(1,552 non-Hispanic whites, 449 African Americans, and
260 Hispanics) (Tables 1 and S4). Genotyping at this stage
included both direct genotyping (ERICH study) and
genome-wide genotyping (GERFHS III and CCC-GCC
studies). Direct genotyping in ERICH included the top
SNP at each locus: rs11179580 for 12q21.1 in lobar ICHThe Amand rs2758605 for 1q22 in nonlobar ICH. For technical
reasons, rs2758605 (second top SNP) was genotyped in
lieu of rs2984613 (r2 ¼ 0.99). The association of chromo-
somal region 1q22 with nonlobar ICH replicated but that
of 12q22.1 with lobar ICH did not. No association was
found between rs11179580, the top SNP at 12q21.1, and
lobar ICH (OR 1.05, 95% CI 0.89–1.24; p ¼ 0.55; meta-
analysis p ¼ 2.6 3 105; Figure 2A). For rs2758605 (1q22)
in nonlobar ICH, each additional C allele was associatederican Journal of Human Genetics 94, 511–521, April 3, 2014 515
Table 2. Loci with p < 1 3 106 in at least One Subtype of Intracerebral Hemorrhage
SNP Characteristics Meta-analysis Discovery Phase
SNP Chr Position Locus
Major/Minor
Allele
Tested
Allelea MAF Type
Gene
Landmarks Trait OR p Q I
rs11179580 12 73586579 12q21.1 C/T C 0.24 intergenic TRHDE all ICH 1.36 7.1 3 107 0.07 61%
lobar ICH 1.56 7.0 3 108 0.43 0%
nonlobar ICH 1.25 0.002 0.03 72%
rs2984613 1 156197380 1q22 C/T C 0.32 intronic PMF1 SLC25A44 all ICH 1.21 6.0 3 104 0.15 48%
lobar ICH 0.97 0.62 0.7 1%
nonlobar ICH 1.44 1.6 3 108 0.05 66%
Abbreviations are as follows: Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; ICH, intracerebral hemorrhage.
aShowing effect estimates when testing the major allele to depict genetic variation associated with increased risk of ICH.with a 24% increase in risk of hemorrhage (95% CI 1.09–
1.40; p ¼ 6.5 3 104; meta-analysis p ¼ 2.2 3 1010;
Figure 2B). When considering ethnic-specific analysis
(Table S6), the association was significant for non-Hispanic
whites (p¼ 0.04) and African Americans (p¼ 13 104) but
not for Hispanics (p ¼ 0.90).
The 1q22 locus contains PMF1 and SLC25A44
(Figure 3A), two genes that code polyamine-modulated fac-
tor 1 and solute carrier family 25-member 44, respectively.
A total of 49 SNPs in this locus achieved p < 1 3 105
(Table S7) and at least one of these was directly genotyped
in all participating studies. Although most of these SNPs
are intronic, rs1052053 has transcriptional impact, result-
ing in substitution of glutamine by arginine in position
75 of exon 2 of PMF1. The resulting transcript variant
(isoform 3) is shorter than isoform 1 and has a distinct
C terminus. This variation has benign functional impact
according to PolyPhen-2 (score 0) and is well tolerated ac-
cording to SIFT (score 1). In addition, rs2241107 is located
in a promoter region in front of PMF1, and this region
also corresponds to a DNase I hypersensitivity region in
all ENCODE cell types.
Expression data fromGTEx show that gene expression in
neural tissues is high for SLC25A44 (Figure S4) and moder-
ate for PMF1 (Figure S5). Moreover, eQTL data from this
same source raises the possibility of 1q22 exerting its
effect by regulating nearby genes, with 27 of the 49 SNPs
mentioned above being associated with expression of
SEMA4A (MIM 607292) in tibial nerve tissue (most signifi-
cant p ¼ 5.3 3 106 for rs6427304, Table S8). Axons, the
main component of peripheral nerves, are extensions of
neurons that, together with the blood vessel wall, extracel-
lular matrix, and glia, form the neurovascular unit, a bio-
logical compartment suggested to play an important role
in cerebrovascular disease.38 SEMA4A is located upstream
of SLC25A44 and codes for semaphorin-4A, a member of
the semaphorin family of soluble and transmembrane pro-
teins that is involved in numerous functions, including
axon guidance, morphogenesis, carcinogenesis, and im-
munomodulation. SEMA4A has moderate-to-high expres-
sion in neural tissues (Figure S6).516 The American Journal of Human Genetics 94, 511–521, April 3, 2Variants known to influence blood pressure did not
significantly affect ICH risk. A total of 172 entries related
to blood pressure were identified in the GWAS catalog.
These corresponded to 72 unique SNPs. None of these
SNPs was significantly associated with all, lobar, or nonlo-
bar ICH after adjusting for multiple testing (Bonferroni-
corrected threshold p < 0.0007, Table S9).Discussion
In this GWAS of ICH, we meta-analyzed data from 3,223
case subjects and 3,725 control subjects and identified
and replicated a susceptibility locus for this condition
located at 1q22 (nonlobar ICH). Importantly, the replica-
tion spanned European- and African-derived ethnicities.
These results confirm previous heritability studies that
indicated that common genetic variation may play an
important role in the occurrence of this condition.15 The
subtype specificity of the identified susceptibility locus is
consistent with the findings of histologic, epidemiologic,
and candidate-gene studies that different mechanisms un-
derlie each ICH subtype. Given the absence of an effective
treatment and the heavy burden imposed by ICH to soci-
ety, the present findings inaugurate the possibility of iden-
tifying novel biological mechanisms involved in causing
this disease that could eventually be targeted by new ther-
apeutic interventions.
Providing important supportive evidence for a role of
1q22 in cerebral small vessel disease, a recent GWAS of
cerebral white matter lesions in healthy adults identified
1q22 as a suggestive locus. Cerebral white matter lesions
constitute a radiological manifestation of cerebral small
vessel disease,39 and several studies have shown that non-
lobar ICH is the most devastating clinical manifestation of
this vasculopathy.40,41 Importantly, several SNPs identified
in our study were also listed in the mentioned GWAS
(Table 3).42 This previous study of white matter hyperin-
tensities informs our GWAS of ICH because the former
was undertaken in individuals of European ancestry, thus
providing crucial support to our findings by confirming014
Figure 2. Meta-analysis Results
Forest plots describing effect estimates for
participating studies, as well as for the
replication effort. Pooled estimates for
odds ratios and 95% confidence intervals
were calculated by fixed effects, inverse
variance weighting meta-analysis.
(A) Association results for rs11179580 at
chromosomal region 12q21.1 in lobar ICH.
(B) Association results for rs2984613 at
chromosomal region1q22 innonlobar ICH.
Results correspond to effect estimates
when testing the major allele to depict
genetic variation associated with increased
risk of ICH.the association between 1q22 and cerebral small disease
in whites. Likewise, our study informs the GWAS of
white matter hyperintensities, because in the latter 1q22
achieved only sub-genome-wide significance (p ¼ 5 3
106).42 In this setting, our findings represent an impor-
tant contribution to definitively establishing the role
of this locus in cerebrovascular disease by taking the asso-
ciation signal beyond the genome-wide threshold and
extending the effect of this genomic region beyond the
realm of imaging endophenotypes to meaningful clinical
impact.
Variants within 1q22 are located in an LD block of 48 kb
that contains PMF1 and SLC25A44 (Figure 3A). PMF1 codes
for polyamine-modulated factor 1, a nuclear protein
regulated by polyamines that is required for normal chro-
mosome alignment and kinetochore formation during
mitosis.43 In conjunction with the transcription factor
NFE2L2 (nuclear factor, erythroid 2-like 2; also known as
NRF2), PMF1 also mediates the transcriptional induction
of SAT1, which codes for an acetyltransferase responsibleThe American Journal of Humafor the rate-limiting enzyme in the
catabolic pathway of polyamine
metabolism.44 Polyamines are pro-
teins with multiple amine groups
that have been linked to cerebrovas-
cular disease by several studies. They
have been found to be elevated in
stroke subjects and to be implicated
in breakdown of the blood-brain bar-
rier45,46 and regulation of the receptor
for the excitatory neurotransmitter
NMDA through a polyamine-specific
binding site.47 SLC25A44 encodes
solute carrier family 25-member 44,
a member of the SLC25 family of
mitochondrial carrier proteins,48 and
no pathological consequences have
been reported so far for genetic varia-
tion within this gene.
Although the lack of replication
of 12q21.1 raises the possibility that
the result of the discovery phasecould be spurious, the consistency in effect estimates
across the discovery cohorts suggests that follow-up
studies should explore this locus further. Identified SNPs
at this locus are located within an intergenic region that
lies 400 kb upstream of TRHDE (Figure 3B), a gene that co-
des for thyrotropin-releasing hormone-degrading enzyme.
However, this gene is located beyond the adjacent recom-
bination hotspot. Four different publicly available data-
bases on eQTLs were queried with no significant findings.
Likewise, data from the ENCODE project were also utilized
to evaluate whether this genomic region contains histone
modification patterns observed in regulatory regions, also
with no significant findings. This locus has not been linked
to other clinical traits.
Several additional complementary analyses could enrich
the results presented here. In particular, evaluation of
gene- and pathway-based association with ICH could allow
identification of both genes and relevant biologic path-
ways involved in causing ICH but that had only sub-GW
results of the present analysis. Additionally, now thatn Genetics 94, 511–521, April 3, 2014 517
Figure 3. Zoom Plots
Regional association results.
(A) Chromosomal region 1q22 in nonlo-
bar ICH.
(B) Chromosomal region 12q21.1 in
lobar ICH.
The index-associated SNP is labeled with
violet color.GW data become available for ICH, joint genetic contribu-
tion to ischemic and hemorrhagic stroke can be assessed,
as well as joint genetic contribution to ICH and white mat-
ter hyperintensities, a widely studied endophenotype for
cerebral small vessel disease.
Our study has limitations. Although we strived to reduce
possible misclassification of cases when assigning lobar
and nonlobar categories, some residual misclassification
may still have occurred. However, it is reasonable to as-
sume that, if present, this misclassification was indepen-
dent and nondifferential, thus biasing our results toward
the null. A second limitation is sample size: although the
discovery cohort was large, additional samples will be crit-
ical to further depict the genetic architecture of ICH and its
subtypes and to better understand how genetic effects vary
by race and ethnicity. Although the null result obtained in
replication for 1q22 in Hispanics could be truly negative—
reflecting heterogeneity of effects across ethnic groups—
power limitations could also account for it. Finally, because
direct genotyping was performed in the majority of sam-
ples included in replication, only self-reported ancestry518 The American Journal of Human Genetics 94, 511–521, April 3, 2014could be utilized to account for popu-
lation structure at that stage.
Importantly, other complex genetic
disorders show that there are probably
numerous susceptibility loci with
small or modest effects that require sig-
nificant increases in sample size to
be discovered.49,50 In this regard, the
overlap of chromosomal region 1q22
with another cerebral-small-vessel-dis-
ease-related trait (white matter hyper-
intensities42) points to the interesting
opportunity of collaborating with
consortia that focus on phenotypes
like cognitive decline, late-life depres-
sion, and non-parkinsonian gait dis-
turbances, all believed to be mediated
to some degree by small vessel diseases
of the brain.
We report a GWAS of ICH, the most
devastating stroke type that currently
has no effective treatment. As has
been the case for ischemic stroke,37,51
careful phenotyping of ICH based on
known differences in cerebrovascular
histopathology proved essential forsuccessful discovery of susceptibility loci. We identified
one susceptibility locus for nonlobar ICH (chromosomal
region 1q22), confirmed through independent replication.
The results of a prior GWAS report of white matter hyper-
intensities, an established risk factor for ICH, provide com-
plementary evidence for a role of 1q22 in cerebral small
vessel disease. The specific biological mechanisms underly-
ing the described associations remain to be elucidated.Supplemental Data
Supplemental Data include six figures and nine tables and can be
found with this article online at http://www.cell.com/ajhg/.
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